Journal Mobile Options
Table of Contents
Vol. 82, No. 1, 2013
Issue release date: November 2012

Nutrient-Based Therapies for Bipolar Disorder: A Systematic Review

Sylvia L.G. · Peters A.T. · Deckersbach T. · Nierenberg A.A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Pharmacotherapy is the first line of treatment for bipolar disorder, but many patients continue to experience persistent subthreshold symptoms. Alternative adjunct treatments, including nutritional therapies, may have the potential to alleviate residual symptoms and improve the outcomes of standard pharmacotherapy. The aim of this paper is to critically review the current clinical evidence and mechanisms of action of nutrient-based therapies alone or in combination with commonly used pharmacotherapies for mania and bipolar depression. Methods: We conducted a Medline search for clinical trials conducted with humans, published in English from 1960 to 2012 using nutritional supplements such as n–3, chromium, inositol, choline, magnesium, folate and tryptophan alone or in combination with pharmacotherapies for the treatment of bipolar disorder. Results: Preliminary data yields conflicting but mainly positive evidence for the use of n–3 fatty acids and chromium in the treatment of bipolar depression. Limited evidence found that inositol may be helpful for bipolar depression, but larger sample sizes are needed. Preliminary randomized, controlled trials suggest that choline, magnesium, folate and tryptophan may be beneficial for reducing symptoms of mania. Conclusions: Given the potential public health impact of identifying adjunct treatments that improve psychiatric as well as physical health outcomes, nutritional treatments appear promising for the management of bipolar disorder but require further study.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Keitner GI, Solomon DA, Ryan CE, Miller IW, Mallinger A, Kupfer DJ, Frank E: Prodromal and residual symptoms in bipolar I disorder. Compr Psychiatry 1996;37:362–367.
  2. Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R: Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007;58:855–863.

    External Resources

  3. Lingam R, Scott J: Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164–172.
  4. Correll CU: Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007;46:687–700.
  5. Culver JL, Arnow BA, Ketter TA: Bipolar disorder: Improving diagnosis and optimizing integrated care. J Clin Psychol 2007;63:73–92.
  6. Simopoulos AP: Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999;70:560S–569S.
  7. Hu FB, Willett WC: Optimal diets for prevention of coronary heart disease. JAMA 2002;288:2569–2578.
  8. Cleland LG, James MJ, Proudman SM: The role of fish oils in the treatment of rheumatoid arthritis. Drugs 2003;63:845–853.
  9. Uauy R, Peirano P, Hoffman D, Mena P, Birch D, Birch E: Role of essential fatty acids in the function of the developing nervous system. Lipids 1996;31(suppl):S167–S176.

    External Resources

  10. Wainwright PE: Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proc Nutr Soc 2002;61:61–69.
  11. Salem N Jr, Litman B, Kim HY, Gawrisch K: Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001;36:945–959.
  12. Horrobin DF, Bennett CN: Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 1999;60:217–234.
  13. Ayton AK, Azaz A, Horrobin DF: A pilot open case series of ethyl-EPA supplementation in the treatment of anorexia nervosa. Prostaglandins Leukot Essent Fatty Acids 2004;71:205–209.
  14. Buydens-Branchey L, Branchey M, Hibbeln JR: Associations between increases in plasma n–3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:568–575.
  15. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 2003;53:56–64.
  16. Holman RT, Adams CE, Nelson RA, Grater SJ, Jaskiewicz JA, Johnson SB, Erdman JW Jr: Patients with anorexia nervosa demonstrate deficiencies of selected essential fatty acids, compensatory changes in nonessential fatty acids and decreased fluidity of plasma lipids. J Nutr 1995;125:901–907.
  17. Kim SY, Breslow RA, Ahn J, Salem N Jr: Alcohol consumption and fatty acid intakes in the 2001–2002 national health and nutrition examination survey. Alcohol Clin Exp Res 2007;31:1407–1414.
  18. Horrobin DF: Essential fatty acids, prostaglandins, and alcoholism: an overview. Alcohol Clin Exp Res 1987;11:2–9.
  19. Green P, Hermesh H, Monselise A, Marom S, Presburger G, Weizman A: Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur Neuropsychopharmacol 2006;16:107–113.
  20. Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913–919.
  21. Peet M, Horrobin DF: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002;36:7–18.
  22. Buydens-Branchey L, Branchey M: n–3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol 2006;26:661–665.
  23. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE: Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486–491.
  24. Killbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC: Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord 2007;9:443–452.
  25. Lee YS: The role of leptin-melanocortin system and human weight regulation: lessons from experiments of nature. Ann Acad Med Singapore 2009;38:34–11.

    External Resources

  26. Lakhan SE, Vieira KF: Nutritional therapies for mental disorders. Nutr J 2008;7:2.
  27. Davison KM, Kaplan BJ: Vitamin and mineral intakes in adults with mood disorders: comparisons to nutrition standards and associations with sociodemographic and clinical variables. J Am Coll Nutr 2011;30:547–558.
  28. Cohen BM, Lipinski JF, Altesman RI: Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J Psychiatry 1982;139:1162–1164.
  29. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
  30. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3. Washington, Psychiatric Press, 1980.
  31. American Psychiatric Association: Diagnostic and Statistical Manual for Mental Disorders, ed 4 (DSM-IV). Washington, Psychiatric Press, 1994.
  32. Fava GA: Unmasking special interest groups: the key to addressing conflicts of interest in medicine. Psychother Psychosom 2010;79:203–207.
  33. Stansby ME: Nutritional properties of fish oils. World Rev Nutr Diet 1969;11:46–105.
  34. Sperling RI, Benincaso AI, Knoell CT, Larkin JK, Austen KF, Robinson DR: Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J Clin Invest 1993;91:651–660.
  35. Tappia PS, Ladha S, Clark DC, Grimble RF: The influence of membrane fluidity, TNF receptor binding, cAMP production and GTPase activity on macrophage cytokine production in rats fed a variety of fat diets. Mol Cell Biochem 1997;166:135–143.
  36. Mischoulon D, Rosenbaum JF: Natural Medications for Psychiatric Disorders: Considering the Alternatives, ed 2. Philadelphia, Lippincott Williams & Wilkins, 2008.
  37. Balanza-Martinez V, Fries GR, Colpo GD, Silveira PP, Portella AK, Tabares-Seisdedos R, Kapczinski F: Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert Rev Neurother 2011;11:1029–1047.

    External Resources

  38. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407–412.
  39. Frangou S, Lewis M, McCrone P: Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006;188:46–50.
  40. Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Duan N, Post RM: Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006;60:1020–1022.
  41. Chiu CC, Huang SY, Chen CC, Su KP: Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry 2005;66:1613–1614.
  42. Osher Y, Bersudsky Y, Belmaker RH: Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 2005;66:726–729.
  43. Sagduyu K, Dokucu ME, Eddy BA, Craigen G, Baldassano CF, Yildiz A: Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J 2005;4:6.

    External Resources

  44. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL: Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr 2009;63:1037–1040.
  45. Wozniak J, Biederman J, Mick E, Waxmonsky J, Hantsoo L, Best C, Cluette-Brown JE, Laposata M: Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 2007;17:440–447.
  46. Marangell LB, Suppes T, Ketter TA, Dennehy EB, Zboyan H, Kertz B, Nierenberg A, Calabrese J, Wisniewski SR, Sachs G: Omega-3 fatty acids in bipolar disorder: clinical and research considerations. Prostaglandins Leukot Essent Fatty Acids 2006;75:315–321.
  47. Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR: Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord 2010;12:142–154.
  48. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH: Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:792–794.
  49. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006;163:210–216.
  50. Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A, Pollock B, Luther J, Buttenfield J, Verfaille S, Kupfer DJ: Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000;2:47–55.
  51. Eden Evins A, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, Nierenberg AA, Sachs GS: Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 2006;8:168–174.
  52. Lyoo IK, Demopulos CM, Hirashima F, Ahn KH, Renshaw PF: Oral choline decreases brain purine levels in lithium-treated subjects with rapid-cycling bipolar disorder: a double-blind trial using proton and lithium magnetic resonance spectroscopy. Bipolar Disord 2003;5:300–306.
  53. Citicoline. Monograph. Altern Med Rev 2008;13:50–57.
  54. Clay HB, Sillivan S, Konradi C: Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011;29:311–324.
  55. Andreazza AC, Shao L, Wang JF, Young LT: Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010;67:360–368.
  56. Chen G, Henter ID, Manji HK: Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry 2010;15:883–895.
  57. Yuksel C, Ongur D: Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010;68:785–794.
  58. Stork C, Renshaw PF: Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005;10:900–919.
  59. Frazier JA, Ahn MS, De Jong S, Bent EK, Breeze JL, Giuliano AJ: Magnetic resonance imaging studies in early-onset bipolar disorder: a critical review. Harv Rev Psychiatry 2005;13:125–140.
  60. Patel NC, Cecil KM, Strakowski SM, Adler CM, Del Bello MP: Neurochemical alterations in adolescent bipolar depression: a proton magnetic resonance spectroscopy pilot study of the prefrontal cortex. J Child Adolesc Psychopharmacol 2008;18:623–627.

    External Resources

  61. Brown ES, Gorman AR, Hynan LS: A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 2007;27:498–502.
  62. Stoll AL, Sachs GS, Cohen BM, Lafer B, Christensen JD, Renshaw PF: Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry 1996;40:382–388.
  63. Schimatschek HF, Rempis R: Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res 2001;14:283–290.
  64. Bowden CL: Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord 2009;11(suppl 2):20–33.

    External Resources

  65. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF: Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008;65:255–263.
  66. Zarate CA, Manji HK: Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 2009;23:569–582.
  67. Siwek M, Wrobel A, Dudek D, Nowak G, Zieba A: The role of copper and magnesium in the pathogenesis and treatment of affective disorders. Psychiatr Pol 2005;39:911–920.
  68. Murck H: Magnesium and affective disorders. Nutr Neurosci 2002;5:375–389.
  69. Giannini AJ, Houser WL Jr, Loiselle RH, Giannini MC, Price WA: Antimanic effects of verapamil. Am J Psychiatry 1984;141:1602–1603.
  70. Giannini AJ, Nakoneczie AM, Melemis SM, Ventresco J, Condon M: Magnesium oxide augmentation of verapamil maintenance therapy in mania. Psychiatry Res 2000;93:83–87.
  71. Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S: Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. Psychiatry Res 1999;89:239–246.
  72. Chouinard G, Beauclair L, Geiser R, Etienne P: A pilot study of magnesium aspartate hydrochloride (magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:171–180.
  73. Horacek J, Kuzmiakova M, Hoschl C, Andel M, Bahbonh R: The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999;24:785–797.
  74. Liu PS, Lin MK: Biphasic effects of chromium compounds on catecholamine secretion from bovine adrenal medullary cells. Toxicology 1997;117:45–53.
  75. McCarty MF: Longevity effect of chromium picolinate – ‘rejuvenation’ of hypothalamic function? Med Hypotheses 1994;43:253–265.
  76. Wright JH, Jacisin JJ, Radin NS, Bell RA: Glucose metabolism in unipolar depression. Br J Psychiatry 1978;132:386–393.
  77. McLeod MN, Gaynes BN, Golden RN: Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J Clin Psychiatry 1999;60:237–240.
  78. McLeod MN, Golden RN: Chromium treatment of depression. Int J Neuropsychopharmacol 2000;3:311–314.
  79. Davidson JR, Abraham K, Connor KM, McLeod MN: Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry 2003;53:261–264.
  80. Amann BL, Mergl R, Vieta E, Born C, Hermisson I, Seemueller F, Dittmann S, Grunze H: A 2-year, open-label pilot study of adjunctive chromium in patients with treatment-resistant rapid-cycling bipolar disorder. J Clin Psychopharmacol 2007;27:104–106.

    External Resources

  81. Mischoulon D, Raab MF: The role of folate in depression and dementia. J Clin Psychiatry 2007;68(suppl 10):28–33.

    External Resources

  82. Calvaresi E, Bryan J: B vitamins, cognition, and aging: a review. J Gerontol B Psychol Sci Soc Sci 2001;56:P327–P339.
  83. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH: Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392–395.
  84. McKeon P, Shelley R, O’Regan S, O’Broin J: Serum and red cell folate and affective morbidity in lithium prophylaxis. Acta Psychiatr Scand 1991;83:199–201.
  85. Bourre JM: Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. 2. Macronutrients. J Nutr Health Aging 2006;10:386–399.
  86. Hannon-Fletcher MP, Armstrong NC, Scott JM, Pentieva K, Bradbury I, Ward M, Strain JJ, Dunn AA, Molloy AM, Kerr MA, McNulty H: Determining bioavailability of food folates in a controlled intervention study. Am J Clin Nutr 2004;80:911–918.
  87. Selhub J, Bagley LC, Miller J, Rosenberg IH: B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71:614S-620S.
  88. Nehra R, Chakrabarti S, Pradhan BK, Khehra N: Comparison of cognitive functions between first- and multi-episode bipolar affective disorders. J Affect Disord 2006;93:185–192.
  89. Reynolds EH: Folic acid, ageing, depression, and dementia. BMJ 2002;324:1512–1515.
  90. Bryan J, Calvaresi E, Hughes D: Short-term folate, vitamin B12 or vitamin B6 supplementation slightly affects memory performance but not mood in women of various ages. J Nutr 2002;132:1345–1356.
  91. Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M: Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. Acta Psychiatr Scand 2009;120:441–445.
  92. Hasanah CI, Khan UA, Musalmah M, Razali SM: Reduced red-cell folate in mania. J Affect Disord 1997;46:95–99.
  93. Carney MW, Chary TK, Laundy M, Bottiglieri T, Chanarin I, Reynolds EH, Toone B: Red cell folate concentrations in psychiatric patients. J Affect Disord 1990;19:207–213.
  94. Lazarou C, Kapsou M: The role of folic acid in prevention and treatment of depression: an overview of existing evidence and implications for practice. Complement Ther Clin Pract 2010;16:161–166.

    External Resources

  95. Coppen A, Bailey J: Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000;60:121–130.
  96. Bell C, Abrams J, Nutt D: Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 2001;178:399–405.
  97. Smith KA, Fairburn CG, Cowen PJ: Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915–919.
  98. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR: Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411–418.
  99. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, Bronen RA, Krystal JH, Duncan J, Rich D, Price LH, Malison R, Dey H, Soufer R, Charney DS: Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 1997;54:364–374.
  100. Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R, Aperia B, Kjellman BF, Mathe AA: Serotonergic ‘vulnerability’ in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr Scand 1998;97:374–380.
  101. Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C, Blier P, Baker GB, Benkelfat C: Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. Neuropsychopharmacology 2000;22:52–63.
  102. Chouinard G: The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. J Psychiatry Neurosci 2006;31:168–176.
  103. Applebaum J, Bersudsky Y, Klein E: Rapid tryptophan depletion as a treatment for acute mania: a double-blind, pilot-controlled study. Bipolar Disord 2007;9:884–887.
  104. Chouinard G, Young SN, Annable L: A controlled clinical trial of l-tryptophan in acute mania. Biol Psychiatry 1985;20:546–557.
  105. Centers for Disease Control: Eosinophilia-myalgia syndrome associated with ingestion of l-tryptophan – United States, through August 24, 1990. JAMA 1990;264:1655.

    External Resources

  106. Kamb ML, Murphy JJ, Jones JL, Caston JC, Nederlof K, Horney LF, Swygert LA, Falk H, Kilbourne EM: Eosinophilia-myalgia syndrome in l-tryptophan-exposed patients. JAMA 1992;267:77–82.
  107. Nordentoft M: Prevention of suicide and attempted suicide in Denmark. Epidemiological studies of suicide and intervention studies in selected risk groups. Dan Med Bull 2007;54:306–369.

    External Resources

  108. Jacka FN, Pasco JA, Mykletun A, Williams LJ, Nicholson GC, Kotowicz MA, Berk M: Diet quality in bipolar disorder in a population-based sample of women. J Affect Disord 2011;129:332–337.

    External Resources

  109. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM: Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002;75:492–498.
  110. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla F: A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 2002;112:803–814.
  111. Kapczinski F, Frey BN, Kauer-Sant’Anna M, Grassi-Oliveira R: Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 2008;8:1101–1113.
  112. Sanchez-Villegas A, Delgado-Rodriguez M, Alonso A, Schlatter J, Lahortiga F, Serra Majem L, Martinez-Gonzalez MA: Association of the Mediterranean dietary pattern with the incidence of depression: The Seguimiento Universidad de Navarra/University of Navarra Follow-Up (SUN) cohort. Arch Gen Psychiatry 2009;66:1090–1098.

    External Resources

  113. Jacka FN, Pasco JA, Mykletun A, Williams LJ, Hodge AM, O’Reilly SL, Nicholson GC, Kotowicz MA, Berk M: Association of western and traditional diets with depression and anxiety in women. Am J Psychiatry 2010;167:305–311.

    External Resources

  114. Akbaraly TN, Brunner EJ, Ferrie JE, Marmot MG, Kivimaki M, Singh-Manoux A: Dietary pattern and depressive symptoms in middle age. Br J Psychiatry 2009;195:408–413.

    External Resources

  115. Jacka FN, Pasco JA, Williams LJ, Mann N, Hodge A, Brazionis L, Berk M: Red meat consumption and mood and anxiety disorders. Psychother Psychosom 2012;81:196–198.

    External Resources

  116. Blair SN, Kohl HW 3rd, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA: Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 1995;273:1093–1098.
  117. Church TS, Earnest CP, Skinner JS, Blair SN: Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA 2007;297:2081–2091.
  118. Cornelissen VA, Fagard RH: Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension 2005;46:667–675.
  119. Sylvia LG, Ametrano RM, Nierenberg AA: Exercise treatment for bipolar disorder: potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. Psychother Psychosom 2010;79:87–96.
  120. Gomes BC, Abreu LN, Brietzke E, Caetano SC, Kleinman A, Nery FG, Lafer B: A randomized controlled trial of cognitive behavioral group therapy for bipolar disorder. Psychother Psychosom 2011;80:144–150.
  121. Miklowitz DJ, Otto MW: Psychosocial interventions for bipolar disorder: A review of literature and introduction of the systematic treatment enhancement program. Psychopharmacol Bull 2007;40:116–131.

    External Resources

  122. Sylvia LG, Nierenberg AA, Stange JP, Peckham AD, Deckersbach T: Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder. J Psychiatr Pract 2011;17:224–232.

    External Resources

  123. Baldessarini RJ, Vazquez G, Tondo L: Treatment of cyclothymic disorder: commentary. Psychother Psychosom 2011;80:131–135.
  124. Fava GA, Rafanelli C, Tomba E, Guidi J, Grandi S: The sequential combination of cognitive behavioral treatment and well-being therapy in cyclothymic disorder. Psychother Psychosom 2011;80:136–143.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50